MA35352B1 - Constructions de liaison à un antigène - Google Patents

Constructions de liaison à un antigène

Info

Publication number
MA35352B1
MA35352B1 MA36759A MA36759A MA35352B1 MA 35352 B1 MA35352 B1 MA 35352B1 MA 36759 A MA36759 A MA 36759A MA 36759 A MA36759 A MA 36759A MA 35352 B1 MA35352 B1 MA 35352B1
Authority
MA
Morocco
Prior art keywords
antigen binding
binding constructs
dimers
constructs
vegf
Prior art date
Application number
MA36759A
Other languages
English (en)
Inventor
Claire Ashman
Ian Richard Catchpole
Zoe Hughes-Thomas
Alan Peter Lewis
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35352(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA35352B1 publication Critical patent/MA35352B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des constructions de liaison à un antigène comprenant un ou deux domaines de liaison à un épitope séparés par une région fc à chaîne unique d'un anticorps, chaque domaine de liaison à un épitope étant apte à se lier au vegf, des dimères comprenant deux constructions de liaison à un antigène de l'invention, des compositions pharmaceutiques comprenant lesdits dimères et leur utilisation dans le traitement de maladies associées à la signalisation par vegf, tel que l'sdème maculaire diabétique (dme), la dégénérescence maculaire liée à l'âge humide (amd humide), la rétinopathie diabétique, l'occlusion veineuse de la rétine (rvo) et la néovascularisation cornéenne, et des séquences polynucléotidiques codant pour lesdites constructions de liaison à un antigène.
MA36759A 2011-07-27 2014-02-18 Constructions de liaison à un antigène MA35352B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512138P 2011-07-27 2011-07-27
PCT/EP2012/064632 WO2013014208A2 (fr) 2011-07-27 2012-07-25 Constructions de liaison à un antigène

Publications (1)

Publication Number Publication Date
MA35352B1 true MA35352B1 (fr) 2014-08-01

Family

ID=46579044

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36759A MA35352B1 (fr) 2011-07-27 2014-02-18 Constructions de liaison à un antigène

Country Status (19)

Country Link
US (2) US9499612B2 (fr)
EP (1) EP2736925A2 (fr)
JP (1) JP5987057B2 (fr)
KR (1) KR101632620B1 (fr)
CN (1) CN103842380A (fr)
AU (1) AU2012288846B2 (fr)
BR (1) BR112014001855A2 (fr)
CA (1) CA2842099A1 (fr)
CL (1) CL2014000204A1 (fr)
CO (1) CO7020847A2 (fr)
CR (1) CR20140047A (fr)
DO (1) DOP2014000017A (fr)
EA (1) EA028886B1 (fr)
HK (1) HK1198446A1 (fr)
MA (1) MA35352B1 (fr)
MX (1) MX2014001019A (fr)
PE (1) PE20141659A1 (fr)
PH (1) PH12014500220A1 (fr)
WO (1) WO2013014208A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
PH12022550313A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2960297A1 (fr) * 2014-11-10 2016-05-19 Genentech, Inc. Anticorps anti-interleukine 33 et leurs utilisations
CA2978026A1 (fr) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Proteines de liaison a la tslp
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
KR20180127344A (ko) * 2016-03-16 2018-11-28 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단백질 A 결합 펩타이드, 항-EphA2 항체 및 이의 사용 방법
US20190119387A1 (en) 2016-04-05 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
EP3565595A4 (fr) * 2017-01-06 2021-03-17 Momenta Pharmaceuticals, Inc. Compositions et procédés associés à des constructions de domaine de liaison à un antigène fc manipulé
CN109021103B (zh) * 2017-06-12 2022-08-23 上海睿智化学研究有限公司 抗人血管内皮生长因子的抗体及其制备方法和应用
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3586860A1 (fr) * 2018-06-22 2020-01-01 Universität Ulm Inhibiteurs de complément et leurs utilisations
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3174680A1 (fr) 2020-03-13 2021-09-16 Genentech, Inc. Anticorps anti-interleukine-33 et leurs utilisations
AR124917A1 (es) * 2021-02-19 2023-05-17 Dotbio Pte Ltd Moléculas de unión a vegfa
WO2023014892A1 (fr) * 2021-08-04 2023-02-09 Alpine Biotherapeutics Corporation Administration intraoculaire durable médiée par des cellules oculaires d'agents thérapeutiques cellulaires pour le traitement de maladies ou de troubles oculaires
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
CN119677771A (zh) * 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 经修饰的融合蛋白及其用途
WO2024055995A1 (fr) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 Protéine de fusion anti-vegfa, son procédé de préparation et son utilisation
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0521985B1 (fr) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101039959A (zh) * 2004-06-30 2007-09-19 杜门蒂斯有限公司 用于治疗炎性疾病的组合物和方法
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP1921090B1 (fr) 2005-07-22 2015-01-14 Kyowa Hakko Kirin Co., Ltd. Composition d'anticorps genetiquement modifie
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
EP2641919A3 (fr) 2007-11-30 2014-05-07 Glaxo Group Limited Produits de construction de liaison à un antigène
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
SI2235064T1 (sl) * 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CA2753287A1 (fr) * 2009-02-24 2010-09-02 Glaxo Group Limited Constructions de liaison d'antigene
US20120076787A1 (en) * 2009-05-28 2012-03-29 Peter Adamson Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AU2010321720B2 (en) * 2009-11-23 2017-03-02 Amgen Inc. Monomeric antibody Fc
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質

Also Published As

Publication number Publication date
MX2014001019A (es) 2014-05-13
DOP2014000017A (es) 2014-04-30
CR20140047A (es) 2014-03-24
PE20141659A1 (es) 2014-11-21
PH12014500220A1 (en) 2019-03-22
WO2013014208A3 (fr) 2013-05-10
US9499612B2 (en) 2016-11-22
AU2012288846B2 (en) 2016-05-19
EA201391812A1 (ru) 2014-06-30
EA028886B1 (ru) 2018-01-31
CO7020847A2 (es) 2014-08-11
JP5987057B2 (ja) 2016-09-06
JP2014523746A (ja) 2014-09-18
HK1198446A1 (en) 2015-04-24
US20140205604A1 (en) 2014-07-24
KR101632620B1 (ko) 2016-06-23
US20170029494A1 (en) 2017-02-02
KR20140041908A (ko) 2014-04-04
CL2014000204A1 (es) 2014-07-25
EP2736925A2 (fr) 2014-06-04
CA2842099A1 (fr) 2013-01-31
CN103842380A (zh) 2014-06-04
WO2013014208A2 (fr) 2013-01-31
AU2012288846A1 (en) 2014-02-06
BR112014001855A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
MA35352B1 (fr) Constructions de liaison à un antigène
Yang et al. Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
Stefanini et al. Anti‐VEGF for the management of diabetic macular edema
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA202091587A1 (ru) Анти-tigit антитела и их применение в качестве терапевтических и диагностических средств
BR112013031198A2 (pt) "anticorpo de ligação à c5ar, seu uso no tratamento de doenças imunológicas e composição farmacêutica que o compreende"
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA40306A1 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA35864B1 (fr) Analogues du glucagon
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MA34726B1 (fr) Prévention des effets secondaires provoqués par des domaines de liaison spécifiques de cd3
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA29625B1 (fr) Immunoglobulines
MA44917A1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
MA50383B1 (fr) Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
EP3682898A4 (fr) Composition pharmaceutique comprenant un anticorps se liant de manière spécifique à l'extrémité n-terminale de la lysyl-arnt synthétase en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la migration des cellules immunitaires
EA201171352A1 (ru) Антигенсвязывающие фрагменты антитела и их применение для лечения или диагностики глазных болезней